Peptide library
Your guide to this compound.
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. GATTEX subcutaneous teduglutide: mean terminal half-life is approximately two hours in healthy subjects and 1.3 hours in adults with short bowel syndrome. Pediatric model estimates were about 0.7 hours at ages 1–11 and 1.0 hour at ages 12–17. Renal impairment increases exposure; these are population-specific estimates, not dose-selection rules. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Adults and children aged one year or older meeting the label’s indication.
The clinical use aims to reduce parenteral-support requirements.
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
GLP-2 receptor agonism supports intestinal absorption.
GLP-2 receptor agonism supports intestinal absorption. Baseline and ongoing gastrointestinal and laboratory monitoring are part of treatment. Renal function affects dosing.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
GATTEX subcutaneous teduglutide: mean terminal half-life is approximately two hours in healthy subjects and 1.3 hours in adults with short bowel syndrome. Pediatric model estimates were about 0.7 hours at ages 1–11 and 1.0 hour at ages 12–17. Renal impairment increases exposure; these are population-specific estimates, not dose-selection rules.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
GATTEX lists no formal contraindications in section 4. This does not remove warnings about neoplastic growth, intestinal obstruction, fluid overload, biliary/pancreatic disease or enhanced absorption of oral medicines.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
GATTEX 5 mg kits/vials: before dispensing, refrigerate at 2–8°C. After pharmacist dispensing, store up to 25°C with a 90-day use-by date; do not freeze or exceed expiry. Reconstituted solution must be used within three hours and unused solution discarded. These limits are presentation-specific.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
Use the supplied GATTEX diluent and the exact kit instructions. After reconstitution, use within three hours, then discard any unused portion. This does not authorize a stored multidose research-vial preparation.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
GATTEX can increase absorption of oral medicines, including benzodiazepines. Its monitoring requirements address gastrointestinal neoplasia/polyps, obstruction, biliary/pancreatic disease and fluid overload. Review sections 5–7 before use.
Named U.S. product only; label revision 20250905. Educational extraction, not complete clinical review.
Primary source · Teduglutide
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.